JP2002504080A - 水痘―帯状疱疹ウィルス遺伝子63産物に対するワクチン - Google Patents
水痘―帯状疱疹ウィルス遺伝子63産物に対するワクチンInfo
- Publication number
- JP2002504080A JP2002504080A JP52814197A JP52814197A JP2002504080A JP 2002504080 A JP2002504080 A JP 2002504080A JP 52814197 A JP52814197 A JP 52814197A JP 52814197 A JP52814197 A JP 52814197A JP 2002504080 A JP2002504080 A JP 2002504080A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- vzv
- pharmaceutical composition
- varicella
- immunologically functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 229960005486 vaccine Drugs 0.000 title description 16
- 241000700605 Viruses Species 0.000 title description 13
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 101710134694 Transcriptional regulator ICP22 homolog Proteins 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 14
- 208000007514 Herpes zoster Diseases 0.000 claims description 13
- 101710176004 Major viral transcription factor ICP4 homolog Proteins 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 201000006082 Chickenpox Diseases 0.000 claims description 6
- 206010046980 Varicella Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims 1
- 208000010531 varicella zoster infection Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 21
- 210000000609 ganglia Anatomy 0.000 description 21
- 101900116756 Varicella-zoster virus Transcriptional regulator ICP22 homolog Proteins 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 208000003098 Ganglion Cysts Diseases 0.000 description 6
- 208000005400 Synovial Cyst Diseases 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940031439 squalene Drugs 0.000 description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 4
- 235000009001 Quillaja saponaria Nutrition 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241001092142 Molina Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 101100525628 Picea mariana SB62 gene Proteins 0.000 description 2
- 241001092473 Quillaja Species 0.000 description 2
- 241001454523 Quillaja saponaria Species 0.000 description 2
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 108010007403 Immediate-Early Proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010037407 Pulmonary hypoplasia Diseases 0.000 description 1
- -1 Quil A Chemical class 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000008615 Zoster Sine Herpete Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 201000003508 omphalocele Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.水痘帯状疱疹ウィルスIE63タンパク質又は免疫学的に機能する誘導体及び 医薬として許容される賦形剤を含む医薬組成物。 2.IE63をコードする核酸又は免疫学的に機能するその誘導体を含む医薬組成 物。 3.医薬における使用のためのIE63遺伝子タンパク質又は免疫学的に機能する その誘導体。 4.水痘又は帯状疱疹の予防又は改善のための医薬の製造のための、IE63タン パク質又は免疫学的に活性なその誘導体の使用。 5.他のVZV抗原をさらに含む、請求項1に記載の医薬組成物。 6.前記第2の水痘帯状疱疹タンパク質が、gpI,gpII,gpIII,gpIV,gpV ,IE62、及び免疫学的に機能するその誘導体から成る群から選ばれる、請求項5 に記載の医薬組成物。 7.アジュバントをさらに含む、請求項1,2,5又は6のいずれか1項に記 載の医薬組成物。 8.前記アジュバントが優先的にTH1応答を誘発する、請求項7に記載の医薬 組成物。 9.前記抗原が、QS21と3D−MPLと共に、油/水エマルジョンとして提示さ れる、請求項9に記載の医薬組成物。 10.請求項1,2,5,6,7,8又は9のいずれか1項に記載の医薬組成物 の安全かつ有効な量を患者に投与することを含む、水痘帯状疱疹ウィルス感染を 患っているか又はそれを受け易い患者を治療する方法。 11.水痘帯状疱疹ウィルスIE63タンパク質、その核酸又は免疫学的に機能する その誘導体を含む医薬組成物の製法であって、上記のタンパク質、核酸又は誘導 体を、医薬として許容される賦形剤と混 合することを含む、前記製法。 12.前記賦形剤がアジュバントを含む、請求項11に記載の製法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9602617.4A GB9602617D0 (en) | 1996-02-09 | 1996-02-09 | Vaccines |
GB9602617.4 | 1996-02-09 | ||
GBGB9626882.6A GB9626882D0 (en) | 1996-12-24 | 1996-12-24 | Vaccines |
GB9626882.6 | 1996-12-24 | ||
PCT/EP1997/000520 WO1997028820A1 (en) | 1996-02-09 | 1997-02-04 | Vaccines against varicella zoster virus gene 63 product |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002504080A true JP2002504080A (ja) | 2002-02-05 |
JP2002504080A5 JP2002504080A5 (ja) | 2004-11-11 |
Family
ID=26308641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52814197A Pending JP2002504080A (ja) | 1996-02-09 | 1997-02-04 | 水痘―帯状疱疹ウィルス遺伝子63産物に対するワクチン |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0879060B1 (ja) |
JP (1) | JP2002504080A (ja) |
KR (1) | KR100365986B1 (ja) |
CN (1) | CN1210470A (ja) |
AR (1) | AR005750A1 (ja) |
AT (1) | ATE390146T1 (ja) |
AU (1) | AU723555B2 (ja) |
BR (1) | BR9707400A (ja) |
CA (1) | CA2245545C (ja) |
CZ (1) | CZ289971B6 (ja) |
DE (1) | DE69738597T2 (ja) |
ES (1) | ES2301175T3 (ja) |
HU (1) | HUP0001991A3 (ja) |
IL (1) | IL125440A (ja) |
NO (1) | NO983617L (ja) |
NZ (1) | NZ331164A (ja) |
PL (1) | PL188457B1 (ja) |
TR (1) | TR199801531T2 (ja) |
TW (1) | TW575427B (ja) |
WO (1) | WO1997028820A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011241A1 (en) * | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
ES2273482T3 (es) * | 1998-03-09 | 2007-05-01 | Glaxosmithkline Biologicals S.A. | Composiciones de vacunas combinadas. |
GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
EP1227840B1 (en) * | 1999-11-03 | 2007-10-03 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
CA2400842C (en) | 2000-02-23 | 2013-01-15 | Smithkline Beecham Biologicals S.A. | Novel compounds |
EA020617B1 (ru) | 2009-05-27 | 2014-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Конструкции casb7439 |
KR101723605B1 (ko) * | 2014-10-21 | 2017-04-07 | 진원생명과학 주식회사 | 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법 |
CN114891830B (zh) * | 2022-04-02 | 2024-03-01 | 武汉博沃生物科技有限公司 | 基于水痘-带状疱疹病毒的重组表达载体、重组病毒及用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952674A (en) * | 1986-05-02 | 1990-08-28 | Merck & Co., Inc. | Vaccine against varicella-zoster virus |
ATE119939T1 (de) * | 1989-06-27 | 1995-04-15 | Smithkline Beecham Biolog | Verbindungen. |
-
1997
- 1997-02-04 IL IL12544097A patent/IL125440A/en not_active IP Right Cessation
- 1997-02-04 ES ES97902334T patent/ES2301175T3/es not_active Expired - Lifetime
- 1997-02-04 JP JP52814197A patent/JP2002504080A/ja active Pending
- 1997-02-04 WO PCT/EP1997/000520 patent/WO1997028820A1/en active IP Right Grant
- 1997-02-04 CZ CZ19982486A patent/CZ289971B6/cs not_active IP Right Cessation
- 1997-02-04 BR BR9707400-4A patent/BR9707400A/pt not_active Application Discontinuation
- 1997-02-04 CA CA002245545A patent/CA2245545C/en not_active Expired - Fee Related
- 1997-02-04 HU HU0001991A patent/HUP0001991A3/hu not_active Application Discontinuation
- 1997-02-04 TR TR1998/01531T patent/TR199801531T2/xx unknown
- 1997-02-04 KR KR10-1998-0706090A patent/KR100365986B1/ko not_active IP Right Cessation
- 1997-02-04 AU AU16012/97A patent/AU723555B2/en not_active Ceased
- 1997-02-04 EP EP97902334A patent/EP0879060B1/en not_active Expired - Lifetime
- 1997-02-04 PL PL97328414A patent/PL188457B1/pl not_active IP Right Cessation
- 1997-02-04 CN CN97192099A patent/CN1210470A/zh active Pending
- 1997-02-04 NZ NZ331164A patent/NZ331164A/en unknown
- 1997-02-04 DE DE69738597T patent/DE69738597T2/de not_active Expired - Fee Related
- 1997-02-04 AT AT97902334T patent/ATE390146T1/de not_active IP Right Cessation
- 1997-02-07 AR ARP970100494A patent/AR005750A1/es not_active Application Discontinuation
- 1997-06-25 TW TW086102043A patent/TW575427B/zh not_active IP Right Cessation
-
1998
- 1998-08-06 NO NO983617A patent/NO983617L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2245545C (en) | 2008-12-30 |
KR19990082360A (ko) | 1999-11-25 |
NO983617L (no) | 1998-10-02 |
TW575427B (en) | 2004-02-11 |
DE69738597T2 (de) | 2008-07-24 |
IL125440A (en) | 2002-02-10 |
CN1210470A (zh) | 1999-03-10 |
DE69738597D1 (de) | 2008-05-08 |
ATE390146T1 (de) | 2008-04-15 |
CA2245545A1 (en) | 1997-08-14 |
NO983617D0 (no) | 1998-08-06 |
WO1997028820A1 (en) | 1997-08-14 |
NZ331164A (en) | 2000-02-28 |
EP0879060B1 (en) | 2008-03-26 |
PL188457B1 (pl) | 2005-02-28 |
TR199801531T2 (xx) | 1998-10-21 |
CZ289971B6 (cs) | 2002-05-15 |
PL328414A1 (en) | 1999-01-18 |
HUP0001991A2 (hu) | 2000-10-28 |
BR9707400A (pt) | 2000-01-04 |
AR005750A1 (es) | 1999-07-14 |
ES2301175T3 (es) | 2008-06-16 |
AU723555B2 (en) | 2000-08-31 |
EP0879060A1 (en) | 1998-11-25 |
CZ248698A3 (cs) | 1998-12-16 |
HUP0001991A3 (en) | 2003-08-28 |
IL125440A0 (en) | 1999-03-12 |
KR100365986B1 (ko) | 2003-02-20 |
AU1601297A (en) | 1997-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2140076T5 (es) | Vacunas que contienen una saponina y un esterol. | |
JP5840167B2 (ja) | 水疱−帯状疱疹ウイルスワクチン | |
JP3530526B2 (ja) | HSV糖蛋白質gDおよび3脱アシル化モノホスホリルリピッドAからなる単純ヘルペスワクチン | |
CN110035772B (zh) | 水痘带状疱疹病毒疫苗 | |
EP0879060B1 (en) | Vaccines against varicella zoster virus gene 63 product | |
CN116655748A (zh) | 一种截短型水痘-带状疱疹病毒gE蛋白及其应用 | |
US7112331B2 (en) | Vaccines against varicella zoster virus gene 63 product | |
US11213582B2 (en) | Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits | |
MXPA98006411A (es) | Vacunas contra producto del gen 63 de virus zoster de varicela | |
WO2022212289A1 (en) | Mutant herpesvirus and vaccine compositions | |
Cheng et al. | A Synergistic Lipid Nanoparticle Encapsulating mRNA Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges | |
CN116212012A (zh) | 复合佐剂以及包含它的疫苗制剂 | |
KR20220149572A (ko) | 지카 바이러스 폴리펩티드 | |
CN117285652A (zh) | 一种包括水痘带状疱疹病毒gE的融合蛋白、其制备方法与应用 | |
CN117122676A (zh) | Hsv免疫原性组合物及其应用 | |
MXPA97008226A (es) | Vacunas que contienen una saponina y un esterol | |
EP2723374A1 (de) | Rekombinantes mistellektin und dessen verwendung als adjuvans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070605 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070704 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070817 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080422 |